Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Assessment of Disease Severity
2.7 Treatment
2.7.1 Treatment Algorithm
2.8 GBI Research Report Guidance
3 Marketed Products
3.1 Product Profile
3.1.1 Spiriva – Boehringer Ingelheim Pharmaceuticals, Pfizer Inc.
3.1.2 Advair Diskus – GlaxoSmithKline
3.1.3 Symbicort – AstraZeneca (Co-promotion with Astellas Pharma Inc)
3.1.4 Combivent– Boehringer Ingelheim
3.1.5 Foradil – Novartis (Co-marketed by Novartis and Schering Corporation)
3.1.6 Arcapta/Onbrez Breezhaler – Novartis
3.1.7 Daliresp – Nycomed
3.1.8 Seebri Breezhaler – Novartis
3.1.9 Striverdi Respimat – Boehringer Ingelheim
3.1.10 Relvar/Breo – GlaxoSmithKline/Theravance
3.1.11 Heat Map – Marketed Products Overview
4 COPD Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.4 Promising Pipeline Molecules
4.4.1 Umeclidinium Bromide – GlaxoSmithKline
4.4.2 Umeclidinium Bromide + Vilanterol – GlaxoSmithKline/Theravance
4.4.3 Vilanterol Trifenatate – GlaxoSmithKline/Theravance
4.4.4 Olodaterol + tiotropium – Boehringer Ingelheim
4.4.5 TD-4208 – Theravance
4.4.6 QVA-149 – Novartis
4.4.7 Andolast (CR 2039) – Rottapharm | Madaus
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products
5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 United States
5.1.3 Top Five Countries of Europe
5.1.4 Japan
5.2 Drivers and Barriers for the COPD Market
5.2.1 Drivers
5.2.2 Barriers
6 Strategic Consolidations
6.1 Major Co-development Deals
6.1.1 Galapagos Enters into Strategic Alliance with Roche
6.1.2 Five Prime Therapeutics Enters into Co-development Agreement with GlaxoSmithKline
6.1.3 Forest Labs Enters into Co-development Agreement with Nycomed
6.2 Major Licensing Deals
6.2.1 Orexo Enters into Licensing Agreement with Ortho-McNeil-Janssen and Janssen Pharmaceutica
6.2.2 Mundipharma Enters into Licensing Agreement with SkyePharma
6.2.3 Evotec Enters into Licensing Agreement with Zhejiang Conba Pharma for EVT 401
6.2.4 Halozyme Therapeutics Enters into Licensing Agreement with Intrexon
7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Pre-clinical
7.1.3 Phase I
7.1.4 Phase II
7.1.5 Phase III
7.1.6 Filed
7.1.7 Undisclosed
7.1.8 Market Forecasts to 2019
7.1.9 The United States
7.1.10 The UK
7.1.11 France
7.1.12 Germany
7.1.13 Italy
7.1.14 Spain
7.1.15 Japan
7.2 Market Definition
7.3 Abbreviations
7.4 References
7.4.1 References for Pipeline Heat Map
7.4.2 References for Marketed Products Heat Map
7.5 Methodology
7.6 Coverage
7.7 Secondary Research
7.8 Therapeutic Landscape
7.9 Epidemiology-Based Forecasting
7.10 Market Size by Geography
7.11 Geographical Landscape
7.12 Pipeline Analysis
7.13 Competitive Landscape
7.13.1 Expert Panel Validation
7.14 Contact Us
7.15 Disclaimer